Citations

Clear

16280 citation(s) found for "Yu, David".

sEEG ‐guided responsive neurostimulation to treat neocortical epilepsy: A multicenter retrospective study of the efficacy and safety of depth electrode‐mediated neuromodulation
Sadeghzadeh, Sina , Purger, David , Bhanot, Priya , Johnson, Noriah , Schonfeld, Ethan , Abikenari, Matthew , Jain, Bhav , Aronson, Joshua P. , Drees, Cornelia , Fisher, Tiffany , Gray, Tyler E. , Ojemann, Steven , Sather, Michael D., Skidmore, Christopher , Yoo, Ji Yeoun , Graber, Kevin , Halpern, Casey H. , Buch, Vivek , Parker, Jonathon J. , Drees, Cornelia , Gray, Tyler E , Hines, Kevin , Karakis, Ioannis , Quraishi, Imran H , Raslan, Ahmed M , Wu, Chengyuan , Yoo, Ji Yeoun , Buch, Vivek , Skidmore, Christopher , Barbosa, Daniel A. N. , Huang, Yuhao , Park, Jay J. , Gerrard, Jason L. , Ghatan, Saadi , Jobst, Barbara C. , Karakis, Ioannis , Willie, Jon T , Wu, Chengyuan

Mayo Clinic

Epilepsia Open | November 18, 2025 | Volume: 11 | Issue: 1 | Pages: 146-161

10.1002/epi4.70180 | PMID 41251192 Get It

Abstract Objectives Pivotal trials have established the effectiveness of the Responsive Neurostimulation System (RNS® System) in treating focal epilepsy. In clinical trials, depth leads were primarily used to treat mesial temporal seizure onsets while cortical strip leads were used to treat neocortical seizure onsets. Here, we systematically analyze the safety and efficacy of stereoelectroencephalography (sEEG)‐guided depth leads to provide responsive stimulation to neocortical gray matter. Methods Patients were stratified as strong responders (>median cohort seizure reduction %), weak responders (>0% and ≤median cohort seizure reduction %), and anti‐responders (≤0%) based on percent seizure reduction at 1 year post‐implant (1‐Y). Pre‐operative T1‐weighted magnetic resonance imaging and post‐operative computed tomography images were merged, and the Euclidean distance between the sEEG epileptic focus (sEEG‐EF) and the nearest RNS System depth lead contacts was calculated. Results A total of 87 depth leads were implanted in 55 patients across neocortical brain regions. The median reduction in clinical seizures improved from 66.7% at 1‐Y to 77.5% at long‐term follow‐up (LTFU: 2.35 ± 0.95 years), with 10 patients (18.2%) achieving complete seizure freedom. Seven patients (12.7%) experienced six serious adverse events. At 1‐Y, shorter Euclidean distance between the sEEG‐EF and RNS System depth leads predicted improved seizure outcome in strong responders ( β = −0.84, p = 0.008) but not in weak responders ( β = 0.21, p = 0.9) or anti‐responders ( β = −20.34, p = 0.11). At LTFU, there was no significant relationship between Euclidean distance and seizure reduction in strong responders ( β = 0.77, p = 0.18), weak responders ( β = 2.05, p = 0.54), or anti‐responders ( β = 0.24, p = 0.99). Exploratory analyses at 1‐Y showed nominal associations between older age ( ρ = 0.32), longer epilepsy duration ( ρ = 0.27), and non‐mesial temporal sEEG‐EFs and greater seizure reduction; however, none survived Bonferroni correction (adjusted α = 0.0027; all post‐correction p > 0.0027), and no associations were observed at LTFU. Significance In this series, neocortical depth leads for RNS therapy had favorable safety and efficacy and proximity to the sEEG‐EF drove initial outcomes for strong responders to RNS therapy. Plain Language Summary In this multi‐center study, patients with difficult‐to‐treat seizures received brain‐responsive stimulation using a device called responsive neurostimulation (RNS), which delivers small electrical pulses to reduce seizures. We focused on patients treated with electrodes placed in the brain's outer regions (the neocortex) and guided by a mapping procedure called sEEG. On average, patients had their seizures cut by two‐thirds after one year and by more than three‐quarters with longer follow‐up, with about one in five becoming seizure‐free. The treatment was safe, and closer electrode placement to the seizure source helped explain early—but not long‐term—improvements.
MRI Analysis of Cardiac Fat, Abdominal Adiposity and Cardiac Function After Vertical Sleeve Gastrectomy in Youth With Type 2 Diabetes
Dobbs, Tyler , Gutierrez, Linnea, Hunter, Kendall S. , Fonseca, Brian, Browne, Lorna P. , Winter, D. , Cree‐Green, Melanie , Pyle, Laura , Hills‐Dunlap, Jonathan L. , Reusch, Jane E.B. , Dobbs, Tyler J , Hu, Houchun Harry , Inge, Thomas H , Gutierrez, Linnea, Hu, Peng , Winter, David, Kelsey, Megan Moriarty , Inge, Thomas H. , Bjornstad, Petter , Nadeau, Kristen J

Mayo Clinic

Pediatric Obesity | November 18, 2025 | Volume: 21 | Issue: 1 | Pages: No page available

10.1111/ijpo.70068 | PMID 41251158 Get It

ABSTRACT Background Adolescents with youth‐onset type 2 diabetes (YO‐T2D) have an increased risk for cardiometabolic complications. The impact of vertical sleeve gastrectomy (VSG) on fat distribution and cardiac morphology/function in YO‐T2D is unknown. Objectives To evaluate changes in body composition, abdominal and cardiac fat depots, and cardiometabolic health in adolescents with YO‐T2D undergoing VSG. Methods Anthropometrics, labs and imaging were used to assess participants pre‐surgery and 3–12 months post‐surgery. MRI quantified pericardial (PAT), epicardial (EAT), subcutaneous (SAT) and visceral adipose tissue (VAT), hepatic fat fraction (HFF) and cardiac morphology/function. Mixed‐effects models assessed longitudinal changes. Results By 12 months, weight decreased from 134.3 ± 5.1 to 103.3 ± 5.2 kg, VAT 1943 ± 148 to 1248 ± 150 cm 3 , HFF 23.2% ± 2.3% to 5.3% ± 2.3% and PAT and EAT by 27% and 33% (all p < 0.01). Homeostatic model assessment of insulin resistance (HOMA‐IR) improved (7.8 ± 1.2 to 1.7 ± 1.2 [ p < 0.01]). BMI, SAT, resting heart rate (RHR), left ventricular (LV) mass and cardiac output (CO) also decreased (all p < 0.05). VAT decreases correlated with decreases in HFF ( r = 0.70, p = 0.01), HOMA‐IR ( r = 0.60, p = 0.04) and CO ( r = 0.70, p = 0.03). HFF decreases correlated with decreases in BMI ( r = 0.70, p = 0.03), HOMA‐IR ( r = 0.90, p < 0.001), RHR ( r = 0.90, p = 0.002), CO ( r = 0.80, p = 0.007) and LV mass ( r = 0.70, p = 0.02). Conclusions VSG reduces ectopic and regional fat and improves associated insulin sensitivity and cardiac health in adolescents with YO‐T2D.
The Value and Yield of Continued Cancer Surveillance of a Surgical HPB Oncology Practice
Thiyagarajan, Sibi Krishna , Verastegui, Alfredo , Hyman, David M. , Tice, Mary, Poruk, Katherine E. , Verastegui, Alfredo , Hyman, David, Poruk, Katherine, C, Luisa Goncalves D, Stauffer, John

Mayo Clinic

The American Surgeon™ | November 18, 2025 | Volume: 92 | Issue: 5 | Pages: 1508-1513

10.1177/00031348251400186 | PMID 41248913 Get It

Introduction Due to rising incidence of Hepato-Pancreato-Biliary (HPB) malignancies and more effective therapies, there are increased survivors after curative surgery but little emphasis is placed on survivorship. This study aims to evaluate the value and yield of postoperative surveillance of surgically treated HPB cancer patients within a single surgeon’s practice. Methods A retrospective 1-year (2024) review identified 128 unique patients with prior surgical resection of a HPB malignancy undergoing active cancer surveillance by the surgical team. We excluded patients with benign indications for surgery or active cancer surveillance outside of the surgical team. Results Of these, 112 (87.5%) and 16 (12.5%) underwent pancreatic and hepatobiliary resection, respectively. Median follow up was 1.5 years from the index operation (IQR: 0.7-2.8 years). Pancreatic pathology was pancreatic adenocarcinoma (PDAC), neuroendocrine, or miscellaneous in 70, 25, and 9 patients, respectively. Hepatobiliary pathology was cholangiocarcinoma (CCA), metastatic colorectal cancer, or hepatocellular carcinoma in 16, 6, and 2 patients, respectively. We identified 12 (9.3%) patients who had findings during the study time period resulting in a repeat HPB surgery. In addition, we identified 12 (9.3%) patients who required referral to another department for additional medical, surgical, or interventional treatments. The remaining 104 (81.2%) patients had findings of either no disease recurrence or stable disease with continued surveillance as a recommendation. Conclusion This study underscores the value of cancer surveillance for HPB cancer patients, demonstrating a yield of nearly 20% of patients with findings requiring repeat surgical intervention or referral to other departments.
Lack of epistatic interaction of SNCA with APOE in synucleinopathies
Saini, Prabhjyot, Estiar, Mehrdad A. , Krohn, Lynne , Mufti, Kheireddin , Ruskey, Jennifer A. , Asayesh, Farnaz , Laurent, Sandra B., Montplaisir, Jacques , Gagnon, Jean‐François , Désautels, Alex , Janes, Francesco , Bernardini, Andrea , Oertel, Wolfgang H. , Janzen, Annette , Figorilli, Michela , Puligheddu, Monica , Mollenhauer, Brit , Trenkwalder, Claudia , Sixel‐Döring, Friederike , Monaca, Christelle, Dijkstra, Femke , Viaene, Mineke , Abril, Beatriz, Anselmi, Victoria, Scholz, Sonja W. , Krohn, Lynne , Mufti, Kheireddin , Arnulf, Isabelle , Dauvilliers, Yves , Kemlink, David , Oertel, Wolfgang H , Kaivola, Karri , Janzen, Annette , Boeve, Brad , Rouleau, Guy Armand , Ibrahim, Abubaker , Stefani, Ambra , Hu, Michele T M , Scholz, Sonja W , Gan-Or, Ziv , Bernardini, Andrea , Janes, Francesco , Figorilli, Michela , Puligheddu, Monica , Yu, Eric , Rudakou, Uladzislau , Spiegelman, Dan , Arnulf, Isabelle , Dauvilliers, Yves , Gigli, Gian Luigi , Valente, Mariarosaria , Šonka, Karel , Plazzi, Giuseppe , Antelmi, Elena , Biscarini, Francesco , Cochen De Cock, Valérie , Heidbreder, Anna , Ferini-Strambi, Luigi , Boeve, Bradley F. , Postuma, Ronald B. , Ibrahim, Abubaker , Stefani, Ambra , Högl, Birgit , Gan‐Or, Ziv

Mayo Clinic

Brain Communications | November 17, 2025 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcaf455 | PMID 41341545 Get It

Abstract Two recent studies suggested that the APOE ε4 haplotype was associated with increased α-synuclein pathology in cell and mouse models. Genetic variants in the SNCA region have strong association with Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and idiopathic REM sleep behaviour disorder (iRBD), while APOE is a genetic risk determinant for only DLB. To determine if genetic-level interactions between SNCA and APOE exists that can explain the protein-level association, we investigated the genotypic interaction of APOE and SNCA in cohorts of PD, DLB and iRBD. We analysed genome-wide association study (GWAS) data from 5229 PD patients and 5480 controls, 2610 DLB patients and 1920 controls, and 1055 iRBD patients and 3667 controls. We used logistic regression interaction models across all three cohorts independently between the (i) top GWAS signals of SNCA single nucleotide polymorphisms (SNPs) and APOE haplotypes and (ii) SNP×SNP and three-way SNP interaction across the entire coding region plus 200 kb flanking each gene. No significant interactions were found to be associated with any of the synucleinopathies after correction for multiple testing. Our results do not support a role for genetic interactions between APOE and SNCA across PD, DLB and iRBD. Since the tested genetic variants affect the expression and function of these proteins, it is likely that any interactions between them do not affect the risk of PD, DLB and iRBD.
External Validation of the Fraser Equation for Estimation of Free Valproate Concentrations in Critically Ill Adults
Brown, Caitlin S. , Liu, JiTong , Riker, Richard R. , Lopez, Natasha , Rosenthal, Eric S. , Zafar, Sahar F. , Gagnon, David J. , Brown, Caitlin S , Liu, JiTong , Lopez, Natasha D , Webb, Andrew

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | November 17, 2025 | Volume: 45 | Issue: 12 | Pages: 831-839

10.1002/phar.70079 | PMID 41246825 Get It

ABSTRACT Background Critically ill patients may be overexposed to valproate because altered protein binding leads to a disproportionate free valproate fraction. The Fraser equation was derived and internally validated to estimate critically ill patients' free valproate concentrations, but it requires external validation. Methods Adult intensive care unit (ICU) patients at two academic centers with concurrently measured free and total valproate concentrations were included. Free valproate concentrations were estimated using the Fraser equation which includes total valproate, albumin and BUN concentration, and whether the patient received propofol or aspirin. The primary outcome was Fraser equation performance, assessed using Bland–Altman methods. Comparative performance against estimates from the Doré equation (an alternative predictive equation), therapeutic concordance using a target free valproate range of 5–15 mg/L, and equation improvements were explored. Results Overall, 315 patients and 556 free‐total valproate concentration pairs were included. The mean (±SD) age was 58 (±17) years and 90 (29%) patients were on valproate prior to hospital admission. The Fraser equation estimated free valproate concentrations were correlated with measured concentrations ( r = 0.728) with a negative bias (mean bias −2.77 mg/L, 95% LOA –18.9, 13.4). The Fraser equation increasingly underestimated measured concentrations as measured concentrations increased. 71% of Fraser equation estimates were therapeutically concordant (e.g., estimate and measured both within reference range) compared to 61.9% of Doré estimates ( p = 0.001). Fraser equation modifications led to minor performance improvements but did not overcome worsening underestimation with higher measured free valproate concentrations. Conclusion The Fraser equation was moderately accurate and corresponded with an appropriate interpretation for 71% of free valproate concentrations. Worse underestimation with higher measured free valproate concentrations suggests direct measurement of free valproate concentrations is warranted. While the Fraser equation could complement therapeutic decision making at centers where direct free valproate measurements are unavailable or slow to return, its accuracy is currently insufficient to replace direct measurement.
The Role of Trendelenburg Positioning for the Acute Symptomatic Management of Spontaneous Intracranial Hypotension
Zhang, Tony , Hooshmand, Sara , Rogers, Nathaniel , Sohutskay, David O , Toledano, Michel , Stitt, Derek , Carabenciov, Ivan D. , Cutsforth‐Gregory, Jeremy K. , Mustafa, Rafid , Hooshmand, Sara J , Rogers, Nathaniel P , Stitt, Derek W, Mustafa, Rafid , Madhavan, Ajay A.

Mayo Clinic

The Neurohospitalist | November 17, 2025 | Volume: 16 | Issue: 3 | Pages: 280-285

10.1177/19418744251399726 | PMID 41262869 Get It

Background Spontaneous intracranial hypotension (SIH) results from cerebrospinal fluid (CSF) leakage due to spinal dural tears or CSF–venous fistulas. Orthostatic headache is the hallmark presentation, though severe downward displacement of the brainstem may lead to altered consciousness or coma. Definitive treatments include targeted epidural blood patches, venous embolization, or surgical repair. Methods This article reviews the role of the Trendelenburg position as a temporizing measure in the acute management of SIH. We describe the correct technique, physiologic rationale, and practical considerations for its application, with attention to both therapeutic and diagnostic utility. Discussion Positioning the patient with the feet elevated above the head can reduce brain sag and provide short-term symptomatic relief while awaiting definitive treatment. Although the Trendelenburg position is widely used in practice, supporting evidence remains limited, and clinicians must be aware of its benefits, indications, and inherent limitations. Its appropriate application may assist in stabilizing patients with acute or severe SIH, particularly those with impaired consciousness, until more definitive interventions are pursued.
Study recruitment challenges when conducting a randomized controlled trial comparing long- and short-acting local anesthetics for pain control after penile prosthesis
Almohtasib, J, Anians, Wyatt, Parikh, Niki , Köhler, Tobias S. , Ziegelmann, Matthew , Almohtasib, Jamil , Helo, Sevann , Ziegelmann, Matthew J, Kohler, Tobias S , Yang, David H.

Mayo Clinic

The Journal of Sexual Medicine | November 15, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.1093/jsxmed/qdaf319 | PMID 41240014 Get It

A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma
Landry, Alexander , Wang, Justin Z. , Patil, Vikas, Ajisebutu, Andrew, Gui, Chloe , Yefet, Leeor, Mamatjan, Yasin , Wei, Qingxia , Singh, Olivia, Mansouri, Sheila , Ehret, Felix , Capper, David , Cohen-Gadol, Aaron A, Behling, Felix , Sloan, Andrew E. , Chambless, Lola B. , Makarenko, Serge , Yip, Stephen , Tsang, Derek S. , Gao, Andrew , Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Santarius, Thomas , Selman, Warren R., Couce, Marta , Wen, Patrick Y. , Walbert, Tobias , Felicella, Michelle M. , Brodie, Chaya , Snyder, James P., Saladino, Andrea , Schichor, Christian , Tonn, Jörg‐Christian, Goldbrunner, Roland , Timmer, Marco , Schimdt, Nils Ole, Jenkinson, Michael D. , Millward, Christopher P. , Islim, Abdurrahman I. , Fl, Behling, Santacroce, Antonio , Schittenhelm, Jens , Raleigh, David R. , Butowski, Nicholas , Westphal, Manfred , Lamszus, Katrin , Mawrin, Christian , Kurz, Sylvia C. , Zada, Gabriel , Yip, Stephen, Zherebitskiy, Viktor, Hnenny, Luke, Dunn, Ian F. , Moliterno, Jennifer , McDermott, Michael , Vogelbaum, Michael A. , Aldape, Kenneth, Alkividias, Tzannis, Short, Susan , Bos, Eelke M. , Dincer, Alper , Paßlack, Peter, Ehret, Felix, Lopez, Clara, Arvaniti, Christina , Benjamin, Carolina , Jackson, Christina , Jeyaretna, Sanjeeva, Scartoni, Daniele , Amelio, Dante , Ivanidze, Jana , Kien, Duong Trung, Millareschavez, Miguel, AlThgafi, Malak, LeRhun, Emilie, Smee, Robert, Muirhead, William , Molina, Eric Suero, Julius, Vitowanu, Chen, J., Mrugała, Maciej M. , Castro, Ana Valeria , Mamatjan, Yasin , Capper, David , Tatagiba, Marcos , Barnholtz-Sloan, Jill S , Yip, Stephen , Aldape, Kenneth , Zadeh, Gelareh , Short, Susan C , Yefet, Leeor S. , Ellenbogen, Yosef , Liu, Jeff , Singh, Olivia , Tabatabai, Ghazaleh , Tatagiba, Marcos , Barnholtz‐Sloan, Jill S. , Mansouri, Alireza , Brastianos, Priscilla K. , Shih, Helen A. , Bi, Wenya Linda , Huang, Raymond Y. , Wen, Patrick Yung , Lee, Ian , Malta, Tathiane Maistro , Castro, Ana Valéria , Noushmehr, Houtan , DiMeco, Francesco , Pollo, Bianca , Kaufmann, Timothy J. , Lachance, Daniel Honore , Giannini, Caterina , Galanis, Evanthia , Raghunathan, Aditya , Hanemann, C. Oliver , Au, Karolyn , Galldiks, Norbert , Herold‐Mende, Christel C. , Sahm, Felix , Jungk, Christine , Jungwirth, Gerhard , Deimling, Andreas von , Drummond, Katharine Jann , Morokoff, Andrew P. , Renovanz, Mirjam , Fougère, Christian la , Perry, Arie , Ricklefs, Franz , Horbinski, Craig , Ng, Ho‐Keung , Snuderl, Matija , Sulman, Erik P. , Cohen‐Gadol, Aaron , Javadpour, Mohsen , Fountain, Daniel Mark , Mathiesen, Tiit Illimar , Pathmanaban, Omar Nathan , Boutros, Paul C. , Fountas, Konstantinos N. , Walsh, Kyle M. , Carvalho, Bruno , Maas, Sybren L. N. , Deng, Maximilian Y. , Mehta, Minesh P. , Odia, Yazmín , Everson, Richard G. , Balogun, James , Calabrese, Evan , Karschnia, Philipp , Teske, Nico , Fariselli, Laura , Greve, Tobias , Ivan, Michael E , Palmer, Joshua D. , Ostrom, Quinn T. , Youngblood, Mark W. , Emerson, Sam, Weller, Michael , Martínez-Pérez, Rafael , Mukherjee, Raj, Cervio, Andrés , Turner, Clinton P. , Chen, Jiawei, Karmur, Brij S. , Neth, Bryan J.

Mayo Clinic

Neuro-Oncology | November 15, 2025 | Volume: 28 | Issue: 2 | Pages: 430-439

10.1093/neuonc/noaf237 | PMID 41259653 Get It

Abstract Background DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed. Methods We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade. Results We first demonstrated that all risk groups benefit from gross total resection. All “high-risk, RT sensitive” tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (P = .003); after subtotal resection (STR), from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (P = .004). “Low-risk, RT sensitive cases” (n = 1207, 61.8%) also benefited from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, P = .03), suggesting that RT be considered in these patients. Neither “low-risk RT resistant” (n = 84, 4.3%) nor “high-risk RT resistant” (n = 356, 18.2%) cases benefited from RT, and the latter group was associated with universally poor outcomes. Conclusions We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.
Pleomorphic Adenoma of the Breast Interpreted as Metaplastic Carcinoma: Awareness of a Rare Entity to Avoid Overtreatment
Youssef, Amal , Supeck, David J. , Downs, Erinn, Ocal, Idris Tolgay, Mina, Lida A. , Sharpe, Richard E. , Ocal, Idris T, Batalini, Felipe

Mayo Clinic

International Journal of Surgical Pathology | November 14, 2025 | Volume: 34 | Issue: 3 | Pages: 690-696

10.1177/10668969251380820 | PMID 41236881 Get It

Pleomorphic adenoma of the breast is a rare tumor, with fewer than 100 patients described in the English literature, mainly as case reports and small case series. Histologically, breast pleomorphic adenoma resembles its more common salivary gland counterpart; however, it can present diagnostic challenges, particularly on core needle biopsy and fine-needle aspiration. The differential diagnosis includes benign and malignant tumors, which carry major treatment implications, from the extent of surgical intervention to the potential use of chemotherapy. Herein we describe a tumor that was initially diagnosed as a triple-negative matrix-producing metaplastic carcinoma, but a secondary review led to the diagnosis of pleomorphic adenoma of the breast. Prior to the secondary review, the patient underwent an excisional biopsy, sentinel lymph node biopsy, and one round of chemotherapy. This report adds to the limited literature surrounding this entity and discusses the differential diagnosis along with histopathologic and immunohistochemical findings that aid in the diagnosis and reviews the radiologic findings observed throughout the patient's clinical course. This patient underscores the difficulty of diagnosis and highlights the need for multidisciplinary consideration and communication to avoid overtreatment.
Highly Coordinated Cochlear Implant Care With Remote Programming: Clinical, Financial, and Implementation Outcomes for the Complete Cochlear Implant Care (CCIC) Model
Nassiri, Ashley M. , Saoji, Aniket A. , DeJong, Melissa D., Tombers, Nicole M. , Lohse, Christine M. , Driscoll, Colin L. W., Neff, Brian A., Haynes, David S. , Daher, Ghazal S. , Carlson, Matthew L., Moriarty, James P. , Borah, Bijan J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | November 14, 2025 | Volume: 47 | Issue: 2 | Pages: e201-e207

10.1097/mao.0000000000004720 | PMID 41236091 Get It

Objective: The Complete Cochlear Implant Care (CCIC) model is a highly coordinated care delivery model reducing and condensing in-person visits for cochlear implant (CI) patients, leveraging telehealth and remote programming. Clinical, quality-of-life, implementation, patient experience, and financial outcomes of the clinical trial are reported. Study design: Prospective, nonrandomized, 2-arm clinical trial Setting: Tertiary referral CI center Patients: Adult CI candidates Interventions: Cochlear implantation Main outcome measures: Speech perception, quality of life, implementation, patient experience, and financial outcomes for both CCIC and traditional care delivery models. Results: Patients participating in the traditional and CCIC delivery models demonstrated 12-month postoperative speech perception scores comparable to nationally reported outcomes (CNC 61% and 72% and AzBio in quiet 75% and 87% for traditional and CCIC cohorts, respectively). Quality-of-life evaluation using the CIQOL-10 demonstrated similar 12-month postoperative scores between groups (52 and 54 for traditional and CCIC cohorts, respectively). The CI Patient Experience Survey demonstrated high satisfaction outcomes in ease of communication, preparedness for surgery, and overall care in both cohorts. Implementation analysis of the CCIC model revealed perceived benefits from staff and clinicians; however, support for expansion of the program was contingent upon the availability of app-based or web-based remote programming technology. Finally, financial analysis revealed decreased out-of-pocket costs for CCIC patients. Conclusion: The CCIC model has the potential to dramatically streamline hearing health care delivery and reduce out-of-pocket costs for CI recipients. Clinical outcomes between cohorts were comparable in this feasibility study; however, a sufficiently powered trial is required to definitively comment on clinical outcomes with the new care delivery model.